Cogprints

Sphingosomes a novel approach to vesicular drug delivery

Swarnlata Saraf., Deepankar Gupta, Chanchal Deep Kaur, Shailendra Saraf, Int J Cur Sci Res. (2011) Sphingosomes a novel approach to vesicular drug delivery. [Journal (Paginated)]

Full text available as:

[img]
Preview
PDF (Sphingosomes a novel approach to vesicular drug delivery) - Published Version
Available under License Creative Commons Attribution No Derivatives.

901Kb

Abstract

Vesicular systems have been realized as extremely useful carrier systems in various scientific domains. Sphingosomes is bilayered vesicles in which an aqueous volume is entirely enclosed by membrane lipid bilayer mainly composed of natural or synthetic sphingolipid. Sphingosomes solve the major drawback of vesicle system (liposomes, niosomes) like less stability, less in vivo circulation time, low tumor loading efficacy in case of cancer therapy. Sphingosomes are clinically used delivery system for chemotherapeutic agent, biological macromolecule and diagnostics. Due to flexibility in size and composition, different types of sphingosomes have been developed. The out come of this review is that sphingosomes represents a promising vesicular drug delivery system to delivers therapeutic compounds for a range of possible applications.

Item Type:Journal (Paginated)
Keywords:sphingosomes, drug delivery, sphingomyelin, vesicular system.
Subjects:JOURNALS
ID Code:7311
Deposited By:CurrentSciDirect Publications, International Journal of Current Scientific Research (IJCSR)
Deposited On:02 May 2011 16:53
Last Modified:02 May 2011 16:53

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

[1] Li VHK, Robinson JR, Lee VHL. Controlled Drug Delivery: Fundamentals and Applications, 2nd Edn., Vol 29, Marcel Dekker, Inc., NY, 1987, pp 7.

[2] Goldberg E. P. Eds. Targeted Drugs. 2nd Edn. New York :Wiley;1983.

[3] Gregoriadis G. Targeting of drugs. Nature 1977;265:407.

[4] Poste G, Kirsch R, Koestler T, Gregoriadis G. Liposomes Technology. Vol 3. Baco Raton: CRC Press Inc.:1983.

[5] Poznansky MJ, Uliano RL. Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol. Rev.1983;36:277.

[6] Erdogan S, Ozer Y, Bilgili H. et al. In vivo behavior of vesicular urokinase. Int J Pharm 2005;295:1-6.

[7] Bangha, AD, Standish M.M, Watkins JG. et al. Diffusion of. univalent ions across the lamellae of swollen phospholipid. J. Mol. Biol.1965;13:238.

[8] Madden TD; Inex Pharmaceutical Corporation. Liposomal camptothecins and uses there of. US Patent 7060828. 2006 June 13.

[9] Allen TM, Ahmed I, Lopes de Menezes DE. et al. Immunoliposome mediated targeting of anti cancer drugs in vivo. Biochem. Soc. Trans. 1995;23:1073.

[10] Kirpotin DB, Lasic DD, Papahadjopoulos D. Medical Applications Of Liposomes Amsterdam: Elsevier;1998..

[11] Mayer LD, Cullis PR, Bally MB. et al. Applications of Liposomes Amsterdam: Elsevier;1998.

[12] Frfkjaer S, Hjorth E, Wfatis, O. et al. Liposome Technology. Vol 1 Boca Raton: CRC Press; 1984.

[13] Hunt C, Tsang S. Int. J. Pharm.1981;8(2):101.

[14] Wong M, Thompson T. Aggregation of dipalmitoylphosphatidylcholine vesicles. Biochemistry 1982;21:4133.

[15] Jain NK. Controlled and novel drug delivery. 1st ed. New Delhi: CBS publishers and distributors; 2001.

[16] Brunke RA. Sphingosomes: properties and potential (liposomes based on sphingolipid) Drug and Cosmetic industry, June 1991.

[17] Hanabiosciences, business wire 2006, http://findarticles.com/p/articles/mi_m0EIN/is_/ai_n26798401

[18] Webb MS, Bally MB, Mayor LD; Inex Pharmaceutical Corporation. Sphingosome for enhanced drug delivery.US Patent 5543152. 1996 June 8.

[19] Webb MS, Bally MB, Mayor LD; Inex Pharmaceutical Corporation. Sphingosomes for enhanced drug delivery. World Patent 035094. 1995 Dec. 28.

[20] Vyas SP, Khar RK. Targeted and controlled drug delivery. Ist edition New Delhi: CBS publisher; 2002.

[21] Biju SS, Talegaonkar S, Mishra PR. et al. Vesicular system: An overview. Indian J Pharm Sci 2006;68:141-153.

[22] Erdogan S, Ozer Y, Bilgili H. et al Thrombus Localization by Using Streptokinase Containing Vesicular Systems. Drug Delivery 2006;13(4):303-309.

[23] Mayer DL, Tai LDL, Bally MB. et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradient. Biochim. Biophys. Acta, 1990;1025:143-151.

[24] Madden TD, Harrigan P, Linda CL. et al., The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem. Phys. Lipid 1990; 53(1):37-46.

[25] Bangham, AD, Standish MM, Watkins JG. et al. Diffusion of. univalent ions across the lamellae of swollen phospholipid. J. Mol. Biol.1965;13;238..

[26] Herremans, A., Liposomes in thrombolytic therapy t-PA targeting with plasminogen-liposomes, a novel concept. The Netherlands Utrecht University:1995.

[27] Mueller R, Hilka T, Nahde T; Vectron therapeutic AG. Drug delivery vehicles and uses theirof. European Patent 1537858. 2005 June 6.

[28] Erdogan S, Ozer Y, Bilgili H. et al Thrombus Localization by Using Streptokinase Containing Vesicular Systems. Drug Delivery 2006;13(4):303-309.

[29] Webb MS, Bally MB, Mayor LD; Inex Pharmaceutical Corporation. Sphingosome for enhanced drug delivery.US Patent 5741516. 1998 April 21.

Metadata

Repository Staff Only: item control page